Metabolism and Target Organ Damage (M&TOD) Maintains an Impact Factor of 3.9 in Latest JCR

Clarivate released the 2025 Journal Citation Reports (JCR) on June 17, 2026. We are pleased to announce that Metabolism and Target Organ Damage (M&TOD) has maintained its Impact Factor of 3.9, ranking 73rd among 198 journals in the Endocrinology & Metabolism category and remaining in Q2 (30%).

This result demonstrates stable year-on-year performance and reflects the journal's continued development since its establishment in September 2021. It also indicates consistent citation impact and sustained academic visibility in the field.

Currently indexed in ESCI and Scopus, M&TOD continues to gain recognition from the international research community for its contributions to the fields of metabolic diseases and target organ damage.

We would like to take this opportunity to thank Editor-in-Chief Prof. Amedeo Lonardo, Co-Editor-in-Chief Prof. Youfei Guan, Honorary Editors Prof. Christopher D. Byrne and Prof. Giovanni Targher, and all members of the international Editorial Board for their continued guidance and support. We also sincerely appreciate the valuable contributions of our reviewers, authors, and readers.

While maintaining steady progress, M&TOD remains committed to supporting high-quality research dissemination through rigorous peer review and robust editorial standards. We look forward to continuing this development together with the global academic community.

Editor: Ashley Chen
Language Editor: Amir Khan
Production Editor: Ting Xu
Respectfully submitted by the Editorial Office of Metabolism and Target Organ Damage